Fractyl Health, Inc.

Contributing Author

Recent Articles by Fractyl Health, Inc.

May-12	Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates GUTS +29.20% GUTS GlobeNewswire
May-11	Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes GUTS GlobeNewswire
May-05	Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference GUTS GlobeNewswire
Mar-24	Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates GUTS +16.17% GUTS GlobeNewswire
Mar-17	Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026 GUTS GlobeNewswire
Feb-26	Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita for Post-GLP-1 Weight Maintenance GUTS -6.19% GlobeNewswire
Jan-29	Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita After GLP-1 Discontinuation GUTS -68.04% GlobeNewswire
Jan-06	Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness GUTS GlobeNewswire
Jan-05	Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category GUTS -8.44% GlobeNewswire
Dec-15	Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones GUTS GlobeNewswire
Dec-02	Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita Procedure GUTS +17.95% GlobeNewswire
Dec-01	Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference GUTS GlobeNewswire
Nov-12	Fractyl Health Reports Third Quarter 2025 Results; Revita Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027 GUTS GlobeNewswire
Nov-05	Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025 GUTS GlobeNewswire
Oct-07	Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity GUTS -6.80% GlobeNewswire
Sep-26	Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock GUTS +32.67% GlobeNewswire
Sep-26	Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita Maintained Weight Loss After GLP-1 Discontinuation GUTS +32.67% GlobeNewswire
Sep-03	Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth GUTS GlobeNewswire
Aug-12	Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates GUTS GlobeNewswire
Aug-07	Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares GUTS GlobeNewswire
Aug-06	Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference GUTS -45.99% GlobeNewswire
Aug-06	Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering GUTS -45.99% GlobeNewswire
Aug-05	Fractyl Health Announces Proposed Public Offering GUTS GlobeNewswire
Aug-05	Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure GUTS -45.99% GUTS GlobeNewswire
Jun-23	Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy GUTS -24.77% GlobeNewswire
Jun-23	Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models GUTS -24.77% GlobeNewswire
Jun-18	Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing GUTS GlobeNewswire
Jun-13	Fractyl Health to Present New Preclinical Data from its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions GUTS -5.07% GlobeNewswire
Jun-04	Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita Across its Bariatric and Metabolic Endoscopy Centers Nationwide GUTS GlobeNewswire
May-19	Fractyl Health Advances Rejuva Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes GUTS +25.44% GlobeNewswire
May-17	Fractyl Health Unveils New Rejuva Smart GLP-1 Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025 GUTS GlobeNewswire
May-13	Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates GUTS -13.28% GUTS GlobeNewswire
May-06	Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference GUTS -7.98% GlobeNewswire

Fractyl Health, Inc.

Recent Articles by Fractyl Health, Inc.

Upgrade your Finviz experience